Clinical trials: Gastric Cancer, completed
Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
This phase Ib trial studies side effects and best dose of dasatinib in preventing oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancers who are receiving FOLFOX regimen with or without bevacizumab.
- Conditions
- Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8
- Trial name
- NCT04164069
- Testing
- Bevacizumab, Dasatinib, Fluorouracil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Anne Noonan
Gastric Cancer, Stomach Cancer
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
This study intends to evaluate the feasibility and treatment efficacy of adding an antibody blocking the epidermal growth factor (EGF) pathway to a neoadjuvant approach with proven efficacy developed at New York University.
- Trial name
- NCT00857246
- Testing
- Cetuximab, Irinotecan, Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Sarcoma, Gastro-intestinal Stromal Tumors (GIST)
Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance
Gastrointestinal stromal tumors (GISTs) are associated with a dismal prognosis in localized and advanced phase with a major resistance to conventional chemotherapy agents.
- Trial name
- NCT00367861
- Testing
- interruption of Glivec®
- Where
- 8 sites in France
- Volunteers
- 564 people
- Sponsor
- Centre Leon Berard
Gastric Adenocarcinoma, GastroEsophageal Cancer
Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with pembrolizumab in subjects with advanced gastric and gastroesophageal adenocarcinoma.
- Trial name
- NCT04164979
- Testing
- Cabozantinib, Pembrolizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, Irvine
Stage II-III Gastric Cancer
A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery (CLASSIC)
The purpose of this study is to validate a pre-defined single-patient classifier algorithm for predicting prognosis and benefit from adjuvant chemotherapy for patients who underwent D2 gastrectomy for stage II and III gastric…
- Trial name
- NCT03403296
- Testing
- nProfiler I Stomach Cancer Assay Kit
- Where
- South Korea
- Volunteers
- 640 people
- Sponsor
- Yonsei University
Gastric Cancer
Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells.
- Trial name
- NCT00004103
- Testing
- cisplatin, floxuridine, irinotecan hydrochloride
- Where
- United States
- Sponsor
- NYU Langone Health
Gastric Cancer
Glycans Bound to Serum Haptoglobin: a Novel Gastric Cancer Tumor Biomarker
The purpose of this study is to evaluate sensitivity and specificity of newly defined tumor biomarker with gastric cancer pts and cancer-free healthy volunteers.
- Trial name
- NCT02848066
- Testing
- Blood sample(10cc) collection
- Where
- South Korea
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Oncology, Metabolic Disease
Nutritional Safety and Metabolic Benefits of Oncometabolic Surgery for Obese Gastric Cancer Patients
The metabolic effect of oncometabolic surgery (long limb Roux-en Y reconstruction) for early gastric cancer patients has been revealed in a few pilot studies.
- Conditions
- Oncology, Metabolic Disease, Gastric Cancer
- Trial name
- ONCOMETAB (NCT03067012)
- Testing
- Oncometabolic reconstruction
- Volunteers
- 20 people
- Sponsor
- Seoul National University Bundang Hospital
Uterine Cervical Neoplasms, Endometrial Neoplasms
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected…
- Conditions
- Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms
- Trial name
- NCT05007106
- Testing
- Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib
- Where
- 73 sites in United States, Canada and 13 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer Adenocarcinoma Metastatic
Docetaxel+Oxali+/-Cetux Met Gastric/GEJ
The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.
- Trial name
- NCT00517829
- Testing
- Docetaxel, cetuximab, oxaliplatin
- Where
- 47 sites in United States
- Volunteers
- 150 people
- Sponsor
- US Oncology Research
Breast Neoplasms, Peritoneal Neoplasms
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
Monoclonal antibodies can transport and deliver radioactive elements capable of releasing sufficient amounts of energy to destroy tumor cells.
- Conditions
- Breast Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT01384253
- Testing
- ²¹²Pb-TCMC-Trastuzumab, trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Orano Med LLC
Gastric Cancer
ERAS for Patients Received Neoadjuvant Chemotherapy
Patients received neoadjuvant chemotherapy with locally advanced gastric caner undergo the enhanced recovery after surgery (ERAS) programs or the standard cares (SC) programs.
- Trial name
- ERASNAC (NCT03272984)
- Testing
- ERAS group, SC group
- Where
- China
- Volunteers
- 114 people
- Sponsor
- JIANG Zhi-Wei
Gastric Cancer
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer
The purpose of this study is to determine the feasibility of chemotherapy, consisting of docetaxel, cisplatin and capecitabine given prior to surgery for stomach cancer.
- Trial name
- DoCCS (NCT01517009)
- Testing
- Docetaxel, cisplatin, Capecitabine
- Where
- 5 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- Jeroen Bosch Ziekenhuis
Gastric Cancer
Development and Validation of a Web-based Nomorgam to Predict Postoperative Complications
The incidence of complications after gastrectomy remains high among elderly patients with gastric cancer. The investigators sought to establish and validate a web-based nomorgam for predicting total complications among elderly…
- Trial name
- NCT05301699
- Testing
- data analysis; validating the nomogram
- Where
- China
- Volunteers
- 582 people
- Sponsor
- Nanjing Medical University
Stomach Neoplasms
Effect of Acupuncture for QoL in Gastric Cancer Patients Undergoing Adjuvant Chemotherapy: a Pilot Study
This is a pilot study evaluating the efficacy of acupuncture on quality of life in gastric cancer patients undergoing postoperative adjuvant chemotherapy.
- Trial name
- NCT03753399
- Testing
- acupuncture
- Where
- 3 sites in China
- Volunteers
- 66 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
OESOPHAGO-GASTRIC CARCINOMA
PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA
Gastric cancer is the fourth commonest cancer and the second largest cause of mortality from cancer. Surgical resection of localised forms of gastric cancer offers the only chance of a cure.
- Trial name
- GASTFOX (NCT03006432)
- Testing
- Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu
- Where
- 134 sites in France, Martinique
- Volunteers
- 507 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Advanced HER2-positive Breast Cancer or Gastric Cancer
Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer
This is a multicenter, open-label, dose escalation, phase I study to estimate the Maximum Tolerated Dose (MTD) or a lower Recommended Dose for Expansion (RDE) of LJM716 in combination with trastuzumab in patients with Human…
- Trial name
- NCT01602406
- Testing
- LJM716, Trastuzumab
- Where
- 11 sites in United States, Belgium and 7 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Gastric Cancer
Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer
The purpose of the phase 1 portion of the study is to determine the safe dose of S-1 and cisplatin that can be administered in gastric cancer patients.
- Trial name
- NCT00072787
- Testing
- S-1, cisplatin
- Where
- 11 sites in United States
- Volunteers
- 41 people
- Sponsor
- Taiho Oncology, Inc.
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) to find out whether it is safe for Chinese participants who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT06549816
- Testing
- sigvotatug vedotin
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.